reports
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
NEOG NEOGEN CORPORATION
LAKE LAKELAND INDUSTRIES INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
ALOT ASTRONOVA INC.
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
PASG PASSAGE BIO
RLAY INC.
CTGO RELAY THERAPEUTICS
TEAF CONTANGO ORE INC.
PROK ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
MIO PROKIDNEY CORP.
DMA PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
ADVM DESTRA MULTI ALTERNATIVE FUND
GF ADVERUM BIOTECHNOLOGIES INC.
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
ORCL ORACLE CORPORATION
NEOG NEOGEN CORPORATION
KEY KEYCORP
FLWS 1-800-FLOWERS.COM CL A
RCII RENT-A-CENTER INC
ESQ ESQUIRE FINANCIAL HOLDINGS
MCFT MASTERCRAFT BOAT HOLDINGS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
PKE PARK AEROSPACE CORPORATION
ALLY GMAC LLC
UAN CVR PARTNERS LP
BYRN BYRNA TECHNOLOGIES INC
BTMD HAYMAKER ACQUISITION CORP III
GTE GRAN TIERRA ENERGY INC.
CVI CVR ENERGY
BATRK INC.
LIBERTY MEDIA CORPORATION
Texas Capital Bancshares, Inc. Appoints Ranjana B. Clark to Board of D...
Texas Capital Bancshares, Inc. Appoints Ranjana B. Clark to Board of Directors DALLAS, April 22, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the appointment of Ranjana B. Clark to its Board of Directors, effective April 15, 2025. Clark will serve as a member of the Audit and Technology Committees. Clark has over 35 years of executive experience in the financial services and technology industries, with previous leadership roles spanning payments, marketing, strategy and business operations. Most recently, sh...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Prefer...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, April 21, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” Th...
Texas Capital Bancshares, Inc. Announces First Quarter 2025 Results
Texas Capital Bancshares, Inc. Announces First Quarter 2025 Results First quarter 2025 net income of $47.0 million and net income available to common stockholders of $42.7 million, or $0.92 per diluted share Strong balance sheet growth with total deposits increasing 9% and total loans growing 7% year-over-year Book Value and Tangible Book Value(1) per share both increasing 11% year-over-year, reaching record levels Capital ratios continue to be strong, including 11.6% CET1 and 15.6% Total Capital DALLAS, April 17, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI),...
Texas Capital President & Chief Executive Officer Rob C. Holmes Now Se...
Texas Capital President & Chief Executive Officer Rob C. Holmes Now Serves as Chairman of the Board DALLAS, April 15, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced that President & Chief Executive Officer Rob C. Holmes was confirmed as Chairman of the Board of Directors at the conclusion of TCBI’s 2025 Annual Meeting of Stockholders. Holmes, who has served as President & Chief Executive Officer and a Director of the Board since 2021, was to this position by the Board of Directors in January 2025. Bob Stalling...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Fina...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. “We believe Ixo-vec is poised to ...
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing...
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Na...
Texas Capital Bancshares, Inc. Announces Date for Q1 2025 Operating Re...
Texas Capital Bancshares, Inc. Announces Date for Q1 2025 Operating Results DALLAS, April 03, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the first quarter of 2025 before market on Thursday, April 17, 2025. Executive management will host a conference call and webcast to discuss first quarter 2025 operating results on Thursday, April 17, 2025, at 9:00 a.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number to ...
Clearside Biomedical to Participate in a Fireside Chat at the 24th Ann...
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the 24th Annual Needham Virtual He...
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets...
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET. The webcast of the fireside chat may be accessed under Events and Presentations in the I...
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Finan...
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside’s SCS Microinjector® - - Management to Host Webcast and Conference Call Today at 4:...
Clearside Biomedical Announces Six Abstracts Accepted for Presentation...
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector® Provides Targeted and Compartmentalized Delivery of Therapeutics Directly to the Retina - ALPHARETTA, Ga., March 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye th...
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Su...
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit - Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development - - Unique Ability to Re-Dose CLS-AX vs Rescue Supports Regulatory & Commercial Strategy - ALPHARETTA, Ga., March 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery o...
- Jonathan Moreland
AAON AAON INC.
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
I3N CHART INDUSTRIES INC.
CDXS CODEXIS
APLE APPLE HOSPITALITY REIT INC
TDW TIDEWATER INC
RC GRUPO RADIO CENTRO S.A.B. DE C.V.
ONEW ONEWATER MARINE
CMTG CLAROS MORTGAGE TRUST
CLVT INC.
VSCO CLARIVATE PLC
MCVT VICTORIA'S SECRET & CO
ECAT MILL CITY VENTURES III LTD
SBGI BLACKROCK ESG CAP ALLOCATION TR
DK SINCLAIR INC
CUBA DELEK US HOLDINGS
VG INC.
FDBC THE HERZFELD CARIBBEAN BASIN FUND
INC.
VENTURE GLOBAL INC.
FIDELITY D & D BANCORP INC
KKR Real Estate Finance Trust Inc. Declares Quarterly Dividend of $0.2...
NEW YORK--(BUSINESS WIRE)-- KKR Real Estate Finance Trust Inc. (the “Company” or “KREF”) (NYSE: KREF) announced that the Board of Directors has declared a dividend of $0.25 per share of common stock with respect to the first quarter of 2025. The dividend is payable on April 15, 2025 to KREF’s common stockholders of record as of March 31, 2025. About KKR Real Estate Finance Trust Inc. KREF is a real estate finance company that focuses primarily on originating and acquiring senior loans secured by commercial real estate properties. KREF is externally managed and advised by an affiliate of KKR ...
Rocky Mountain Chocolate Factory Appoints Brian Quinn to Its Board of ...
Rocky Mountain Chocolate Factory Appoints Brian Quinn to Its Board of Directors DURANGO, Colo., March 13, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, today announced that Brian Quinn has been appointed to the Company’s Board of Directors (the “Board”), where he will serve on the Company’s Nominating and Corporate Governance, Audit, and Compensation Committees. Mr. Quinn is an accomplished business leader with ...
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Finan...
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast ...
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with ...
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD - CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development - ALPHARETTA, Ga., March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to th...
KKR Real Estate Finance Trust Inc. Announces Closing of New $550 Milli...
NEW YORK--(BUSINESS WIRE)-- KKR Real Estate Finance Trust Inc. (“KREF”) (NYSE: KREF) announced today that it closed on a Term Loan B (the “New Term Loan B”) for an aggregate principal amount of $550 million due in 2032. KREF intends to use the net proceeds from the New Term Loan B to repay the existing Term Loan B due in 2027, repay other indebtedness and for general corporate purposes. The New Term Loan B priced at 99.875% and bears interest at SOFR plus 325 basis points. Patrick Mattson, President and Chief Operating Officer of KREF, stated: “KREF is pleased to grow its presence in the Term...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.